Therapeutic effects of nandrolone decanoate, tibolone, lynestrenol and ethylestrenol on Sjögren's syndrome-like disorder in NZB/W mice.
Growth of mononuclear cell infiltration in submandibular glands is significantly inhibited by Org OD14 (tibolone), lynestrenol and ethylestrenol given orally to New Zealand Black/White (NZB/W) mice from 26 weeks of age onwards. In addition, the extent of already established mononuclear cell infiltrations is significantly inhibited and reduced by nandrolone decanoate injected from 43 weeks of age onwards. Tibolone and nandrolone decanoate are the most potent of the four drugs. The therapeutic effect of these four steroids on the Sjögren's syndrome-like disorder in NZB/W mice is not related to their endocrine activities.
D000818:Animals; D001327:Autoimmune Diseases / Q000188:drug therapy*; D002465:Cell Movement / Q000187:drug effects; D005032:Ethylestrenol / Q000627:therapeutic use; D005260:Female; D007962:Leukocytes / Q000502:physiology; D008234:Lynestrenol / Q000627:therapeutic use; D008297:Male; D051379:Mice; D008814:Mice, Inbred NZB; D009277:Nandrolone / Q000031:analogs & derivatives / Q000627:therapeutic use; D000077603:Nandrolone Decanoate; D009652:Norpregnenes / Q000627:therapeutic use; D012859:Sjogren's Syndrome / Q000188:drug therapy*; D013256:Steroids / Q000627:therapeutic use*; D013363:Submandibular Gland / Q000473:pathology
D009652:Norpregnenes; D013256:Steroids; D009277:Nandrolone; D005032:Ethylestrenol; C027385:tibolone; D000077603:Nandrolone Decanoate; D008234:Lynestrenol